Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia.
par Fayyad Kazan, Hussein 
;Bitar, Nizar;Najar, Mehdi ;Lewalle, Philippe ;Fayyad Kazan, Mohammad ;Badran, Rabih ;Hamade, Eva;Daher, Ahmad;Hussein, Nader;ElDirani, Rim;Berri, Fadwa;Vanhamme, Luc ;Burny, Arsène ;Martiat, Philippe ;Rouas, Redouane ;Badran, Bassam
Référence Journal of translational medicine, 11, page (31)
Publication Publié, 2013
;Bitar, Nizar;Najar, Mehdi ;Lewalle, Philippe ;Fayyad Kazan, Mohammad ;Badran, Rabih ;Hamade, Eva;Daher, Ahmad;Hussein, Nader;ElDirani, Rim;Berri, Fadwa;Vanhamme, Luc ;Burny, Arsène ;Martiat, Philippe ;Rouas, Redouane ;Badran, Bassam Référence Journal of translational medicine, 11, page (31)
Publication Publié, 2013
Article révisé par les pairs
| Résumé : | MicroRNAs (miRNAs) are small (19-22-nt) single-stranded noncoding RNA molecules whose deregulation of expression can contribute to human disease including the multistep processes of carcinogenesis in human. Circulating miRNAs are emerging biomarkers in many diseases and cancers such as type 2 diabetes, pulmonary disease, colorectal cancer, and gastric cancer among others; however, defining a plasma miRNA signature in acute myeloblastic leukemia (AML) that could serve as a biomarker for diagnosis or in the follow-up has not been done yet. |
